Navigation Links
Feinstein Institute Scientist Wins Crafoord Award from Royal Swedish Academy of Sciences for Arthritis Research
Date:1/19/2013

MANHASSET, NY (PRWEB) January 19, 2013

The Royal Swedish Academy of Sciences announced today that Peter K. Gregersen, MD, a scientist at The Feinstein Institute for Medical Research, will receive the prestigious Crafoord Prize for his genetic research in the area rheumatoid arthritis.

Dr. Gregersen, center head of the Feinstein Institute's Robert S. Boas Center for Genomics and Human Genetics in Manhasset, NY, will be formally presented with the award on May 2 by the King of Sweden, Carl XVI Gustaf.

Dr. Gregersen and two collaborators, Robert Winchester, MD, professor of medicine in the Division of Rheumatology at New York Presbyterian Hospital, and Lars Klareskog, MD, a professor at Stockholm's Karolinska Institute, are being honored for their discoveries concerning the role of different genetic factors and their interactions with environmental factors in the pathogenesis, diagnosis and clinical management of rheumatoid arthritis," the Royal Swedish Academy of Sciences said in announcing its Crafoord Prize in Polyarthritis.

“The knowledge acquired by the 2013 Crafoord Laureates opens new possibilities for the prevention and better treatment of rheumatoid arthritis. Their focused detective work has resulted in a hypothesis that the disease arises from the interplay between genetic inheritance and environmental influences,” the Royal Academy said of Drs. Gregersen, Winchester and Klareskog. “According to this premise, joint problems from rheumatoid arthritis may start in another part of the body: the lungs.”

Dr. Gregersen will split a $600,000 award with his two colleagues.

Dr. Gregersen has mounted collaborations across the world in an effort to expand the numbers of genetic specimens used to identify specific disease genes, with an emphasis on autoimmune disorders. The North American Rheumatoid Arthritis Consortium, directed by Dr. Gregersen, has identified several major risk genes for rheumatoid arthritis.

To see a video of Dr. Gregersen speaking about the Craaford Award and his rheumatoid arthritis research, click here.

Here is a link to a news release about the award issued this morning by the Royal Swedish Academy of Science: click here

About The Feinstein Institute for Medical Research Headquartered in Manhasset, NY, The Feinstein Institute for Medical Research is home to international scientific leaders in many areas including Parkinson's disease, Alzheimer’s disease, psychiatric disorders, rheumatoid arthritis, lupus, sepsis, human genetics, pulmonary hypertension, leukemia, neuroimmunology, and medicinal chemistry. The Feinstein Institute, part of the North Shore-LIJ Health System, ranks in the top 5th percentile of all National Institutes of Health grants awarded to research centers. For more information visit http://www.FeinsteinInstitute.org

Read the full story at http://www.prweb.com/releases/2013/1/prweb10336613.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Feinstein Institute to receive grant to improve schizophrenia treatment
2. Feinstein Institute to Receive Grant from Centers for Medicare & Medicaid Services to Improve Schizophrenia Treatment
3. Feinstein Institute researchers discover that bean used in Chinese food could protect against sepsis
4. Feinstein announces submission of new drug application for diagnosing parkinsonian syndromes
5. Feinstein Institute researchers discover plant derivative
6. A Feinstein Institute for Medical Research Study Shows Early Cognitive Problems among Those Who Eventually Get Alzheimer's
7. David H. Koch donates $10 million to Mount Sinais Jaffe Food Allergy Institute
8. Bascom Palmer Eye Institute announces breakthrough for degenerative vision disorder
9. The Ludwig Institute for Cancer Research announces launch of iTeos Therapeutics SA
10. A North American first at the Montreal Heart Institute
11. UC Santa Barbaras Kavli Institute receives 2 grants to explore interface of physics and biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
(Date:10/13/2017)... ... 13, 2017 , ... Talented host, actor Rob Lowe, is ... a new episode of "Success Files," which is an award-winning educational program broadcasted ... each subject in-depth with passion and integrity. , Sciatica occurs when the sciatic ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & Wellness ... Moonlight to raise money for the American Heart Association Heart Walk. Teams of up ... work together to keep their treadmills moving for 5 hours. Treadmills will start at ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... -- Cohen Veterans Bioscience and Early Signal Foundation announce ... home sensors for real-time monitoring of patients with trauma-related ... organization focused on disruptive health solutions for rare disorders ... to record and integrate behavioral, cognitive, physiological and contextual ... ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
Breaking Medicine Technology: